Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, via Pupilli n1, cap 40136 Bologna, Italy.
Expert Rev Anticancer Ther. 2011 Feb;11(2):217-27. doi: 10.1586/era.10.172.
Despite advances in diagnostic imaging, the evolution of neoadjuvant chemotherapy and the refinements in limb-salvage surgery, the progression-free survival rate remains poor for patients with metastatic, recurrent or unresectable osteosarcoma. Different therapeutic strategies for these subgroups of patients have been employed to control disease and prolong survival. Treatment options are limited and controversial, including systemic and localized therapies. Surgical resection, whenever feasible, is still the standard treatment in advanced osteosarcoma. The role of chemotherapy is unclear while the use of radiotherapy, embolization and thermal ablation is increasing. New therapeutic experimental approaches and novel target therapies are needed to improve the outcome of these subgroups of patients.
尽管在诊断成像方面取得了进展，新辅助化疗的发展以及保肢手术的改进，转移性、复发性或不可切除的骨肉瘤患者的无进展生存率仍然很差。已经采用了不同的治疗策略来控制这些亚组患者的疾病并延长生存时间。治疗选择有限且存在争议，包括全身和局部治疗。只要可行，手术切除仍然是晚期骨肉瘤的标准治疗方法。化疗的作用尚不清楚，而放疗、栓塞和热消融的使用正在增加。需要新的治疗实验方法和新的靶向治疗来改善这些亚组患者的预后。
